The cancer burden in Europe, with millions of new cases and deaths annually, poses challenges for healthcare systems. Tackling this
requires solutions that integrate technologies, infrastructures, and collaborative frameworks. The SPARC project focuses on
addressing high-incidence cancers, such as lung and breast cancers, as well as rare cancers like neuroblastoma, by advancing
diagnostics, improving care access, and enhancing patient outcomes. SPARC aligns with the key pillars of the forthcoming Joint
Action on Personalized Medicine, ensuring a complementary approach to Member State strategies. Building on initiatives like
"Cancer Diagnostic and Treatment for All" and "Genomics for Public Health," SPARC addresses critical gaps in precision medicine.
Through pilot studies (on lung, pancreatic, neuroblastoma, hematological malignancies, adrenocortical carcinoma, and melanoma
cancers) the project establishes standardized protocols, harmonizes data, and fosters cross-border collaboration. SPARC emphasizes
the use of advanced tools like liquid biopsy, next-generation sequencing, and AI-powered diagnostics to ensure precision care.
Molecular tumor boards are integrated to enhance multidisciplinary decision-making, strengthen genomic expertise, and mitigate
workforce shortages. SPARC’s transnational strategy engages 8 Member States delivering tailored solutions to reduce disparities in
healthcare access and resources. By engaging healthcare professionals, patient organizations, policymakers, researchers, industry
leaders, and private-sector partners, SPARC ensures a multi-stakeholder framework for advancing precision oncology. To overcome
barriers to health literacy, SPARC develops multilingual resources for patients and training programs for healthcare professionals
fostering trust and expertise in personalized medicine. Sustainability is a cornerstone of SPARC, with efforts to harmonize practices,
integrate precision medicine into national frameworks, and ensure impact.